YBL-018

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameYBL-018

Drug Alias NameB7-H3/CD3 antibody, Y BiologicsB7H3/ALiCESDA-0156YBL-018SDA0156 +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD276Anti-CD3

TargetsCD276 antigenT cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesY-biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesY-biologics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A